$1.08 Billion is the total value of Sofinnova Investments, Inc.'s 150 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 55.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VRTX | Sell | Vertex Pharmaceuticals Inc | $20,384,000 | -33.1% | 85,664 | -38.4% | 1.89% | -14.1% |
| BMRN | Sell | Biomarin Pharmaceutical Inc | $20,284,000 | -45.7% | 240,046 | -45.7% | 1.88% | -30.3% |
| BIIB | Sell | Biogen Inc | $16,650,000 | -11.9% | 52,628 | -17.4% | 1.54% | +13.0% |
| PTCT | Sell | PTC Therapeutics Inc | $13,035,000 | -47.5% | 292,217 | -43.5% | 1.21% | -32.6% |
| MYOK | Sell | MyoKardia Inc | $8,209,000 | -42.5% | 175,118 | -10.6% | 0.76% | -26.2% |
| KDMN | Sell | Kadmon Holdings Inc | $6,395,000 | -40.4% | 1,526,178 | -35.6% | 0.59% | -23.5% |
| CALA | Sell | Calithera Biosciences Inc | $3,636,000 | -56.4% | 819,002 | -43.9% | 0.34% | -44.0% |
| Sell | Alnylam Pharmaceuticals Inccall | $2,949,000 | -74.4% | 27,100 | -72.9% | 0.27% | -67.1% | |
| TGTX | Sell | TG Therapeutics Inc | $2,709,000 | -69.9% | 275,305 | -66.1% | 0.25% | -61.3% |
| CCXI | Sell | ChemoCentryx Inc | $2,680,000 | -82.0% | 66,695 | -82.3% | 0.25% | -76.9% |
| ZYME | Sell | Zymeworks Inc | $1,774,000 | -63.7% | 49,989 | -53.5% | 0.16% | -53.4% |
| BCRX | Sell | BioCryst Pharmaceuticals Inc | $1,632,000 | -78.0% | 815,690 | -62.1% | 0.15% | -71.8% |
| FATE | Sell | Fate Therapeutics Inc | $812,000 | -93.5% | 36,564 | -94.2% | 0.08% | -91.6% |
| RYTM | Exit | Rhythm Pharmaceuticals Inc | $0 | – | -21,319 | -100.0% | -0.04% | – |
| HALO | Exit | Halozyme Therapeutics Inc | $0 | – | -72,481 | -100.0% | -0.09% | – |
| DRNA | Exit | Dicerna Pharmaceuticals Inc | $0 | – | -159,512 | -100.0% | -0.25% | – |
| APLT | Exit | Applied Therapeutics Inc | $0 | – | -134,825 | -100.0% | -0.26% | – |
| FOMX | Exit | Foamix Pharmaceuticals Ltd | $0 | – | -1,162,176 | -100.0% | -0.28% | – |
| ORTX | Exit | Orchard Therapeutics PLCadr | $0 | – | -283,406 | -100.0% | -0.28% | – |
| XBIT | Exit | XBiotech Inc | $0 | – | -240,995 | -100.0% | -0.32% | – |
| FTSV | Exit | Forty Seven Inc | $0 | – | -138,643 | -100.0% | -0.39% | – |
| SGEN | Exit | Seattle Genetics Inc | $0 | – | -50,000 | -100.0% | -0.41% | – |
| ARQL | Exit | ArQule Inc | $0 | – | -387,469 | -100.0% | -0.56% | – |
| Exit | Alexion Pharmaceuticals Inccall | $0 | – | -75,000 | -100.0% | -0.58% | – | |
| DERM | Exit | Dermira Inc | $0 | – | -545,466 | -100.0% | -0.60% | – |
| Exit | Medicines Coput | $0 | – | -110,000 | -100.0% | -0.67% | – | |
| MGNX | Exit | MacroGenics Inc | $0 | – | -1,173,882 | -100.0% | -0.92% | – |
| MRTX | Exit | Mirati Therapeutics Inc | $0 | – | -108,383 | -100.0% | -1.01% | – |
| REGN | Exit | Regeneron Pharmaceuticals Inc | $0 | – | -50,086 | -100.0% | -1.36% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.